Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 8 studies | 22% ± 8% | |
| endothelial cell | 7 studies | 23% ± 4% | |
| oligodendrocyte | 7 studies | 22% ± 7% | |
| mesothelial cell | 5 studies | 25% ± 18% | |
| pericyte | 4 studies | 22% ± 3% | |
| adipocyte | 4 studies | 21% ± 8% | |
| fibroblast | 3 studies | 30% ± 10% | |
| squamous epithelial cell | 3 studies | 33% ± 18% | |
| epithelial cell | 3 studies | 42% ± 21% |
Insufficient scRNA-seq data for expression of AMOTL2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 99% | 7367.24 | 1430 / 1445 | 98% | 33.04 | 180 / 183 |
| breast | 100% | 11602.80 | 458 / 459 | 97% | 34.38 | 1086 / 1118 |
| kidney | 98% | 4549.66 | 87 / 89 | 98% | 54.51 | 885 / 901 |
| lung | 98% | 6995.74 | 567 / 578 | 97% | 28.66 | 1115 / 1155 |
| uterus | 100% | 7888.92 | 170 / 170 | 94% | 36.50 | 432 / 459 |
| thymus | 100% | 6420.91 | 650 / 653 | 92% | 43.99 | 558 / 605 |
| ovary | 92% | 4163.70 | 165 / 180 | 99% | 59.30 | 427 / 430 |
| prostate | 98% | 5074.31 | 239 / 245 | 93% | 24.55 | 468 / 502 |
| skin | 100% | 10426.95 | 1807 / 1809 | 91% | 27.13 | 428 / 472 |
| stomach | 92% | 3635.65 | 329 / 359 | 95% | 23.61 | 272 / 286 |
| bladder | 100% | 5523.86 | 21 / 21 | 86% | 21.48 | 432 / 504 |
| intestine | 88% | 4134.76 | 846 / 966 | 93% | 20.65 | 491 / 527 |
| brain | 74% | 2089.82 | 1944 / 2642 | 99% | 56.46 | 695 / 705 |
| pancreas | 66% | 1620.91 | 215 / 328 | 94% | 25.21 | 168 / 178 |
| liver | 55% | 1242.62 | 125 / 226 | 53% | 10.71 | 217 / 406 |
| adrenal gland | 72% | 1896.07 | 187 / 258 | 33% | 4.96 | 76 / 230 |
| adipose | 100% | 14277.86 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 98% | 8284.64 | 1308 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 94% | 3345.23 | 226 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 94% | 25.54 | 75 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 29.95 | 42 / 45 |
| heart | 81% | 2984.55 | 698 / 861 | 0% | 0 | 0 / 0 |
| muscle | 57% | 1537.69 | 461 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.53 | 1 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001525 | Biological process | angiogenesis |
| GO_0030036 | Biological process | actin cytoskeleton organization |
| GO_0016055 | Biological process | Wnt signaling pathway |
| GO_0030334 | Biological process | regulation of cell migration |
| GO_0035329 | Biological process | hippo signaling |
| GO_0003365 | Biological process | establishment of cell polarity involved in ameboidal cell migration |
| GO_0005829 | Cellular component | cytosol |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0031410 | Cellular component | cytoplasmic vesicle |
| GO_0055037 | Cellular component | recycling endosome |
| GO_0005923 | Cellular component | bicellular tight junction |
| GO_0005515 | Molecular function | protein binding |
| Gene name | AMOTL2 |
| Protein name | Angiomotin-like protein 2 (Leman coiled-coil protein) (LCCP) Angiomotin like 2 |
| Synonyms | KIAA0989 |
| Description | FUNCTION: Regulates the translocation of phosphorylated SRC to peripheral cell-matrix adhesion sites. Required for proper architecture of actin filaments. Inhibits the Wnt/beta-catenin signaling pathway, probably by recruiting CTNNB1 to recycling endosomes and hence preventing its translocation to the nucleus. Participates in angiogenesis. May play a role in the polarity, proliferation and migration of endothelial cells. Selectively promotes FGF-induced MAPK activation through SRC. . |
| Accessions | ENST00000515172.1 D6RIC7 ENST00000514516.5 [Q9Y2J4-4] ENST00000513145.1 [Q9Y2J4-3] ENST00000505596.1 ENST00000422605.6 [Q9Y2J4-1] ENST00000249883.10 [Q9Y2J4-2] ENST00000506107.1 D6RCL7 ENST00000504234.1 D6RJA4 ENST00000502491.1 D6RFG0 ENST00000510560.1 Q9Y2J4 D6RF61 D6RBK2 |
